Lyra Therapeutics Inc (LYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lyra Therapeutics Inc (LYRA) has a cash flow conversion efficiency ratio of 0.566x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.07 Million) by net assets ($-10.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lyra Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Lyra Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Lyra Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lyra Therapeutics Inc (LYRA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Lyra Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lyra Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thunder Power Holdings, Inc.
NASDAQ:AIEV
|
-0.049x |
|
Augmentum Fintech PLC
LSE:AUGM
|
-0.009x |
|
HSS Hire Group PLC
LSE:HSS
|
0.141x |
|
EUROPA MET. LTD POST CONS
F:WRE1
|
N/A |
|
Agronomics Ltd
LSE:ANIC
|
-0.005x |
|
Ridgetech, Inc.
NASDAQ:RDGT
|
0.180x |
|
Diagonal Bio AB
ST:DIABIO
|
-0.084x |
|
Greencastle Resources Ltd.
V:VGN
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Lyra Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lyra Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see LYRA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.72 Million | $-28.86 Million | 2.693x | +144.59% |
| 2024-12-31 | $11.59 Million | $-70.01 Million | -6.039x | -752.98% |
| 2023-12-31 | $89.42 Million | $-63.30 Million | -0.708x | -31.77% |
| 2022-12-31 | $80.75 Million | $-43.38 Million | -0.537x | +28.60% |
| 2021-12-31 | $34.32 Million | $-25.82 Million | -0.752x | -165.10% |
| 2020-12-31 | $74.49 Million | $-21.14 Million | -0.284x | +84.88% |
| 2019-12-31 | $7.33 Million | $-13.75 Million | -1.877x | -3126.63% |
| 2018-12-31 | $-107.07 Million | $-6.64 Million | 0.062x | -- |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-infla… Read more